{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-008200","form_type":"8-K","ticker":"QCLS","cik":"0001321834","company_name":"Q/C TECHNOLOGIES, INC.","filed_at":"2023-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.386477+00:00","generated_at":"2026-06-17T22:54:02.514213+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MyMD Pharmaceuticals announces positive preclinical data for MYMD-1 in RA model","bullets":["MYMD-1 reduced histopathological changes vs placebo (p<0.0001 composite score) in RA model.","Disease severity reduced 47% with MYMD-1 450 mg/kg/day orally vs 37% for etanercept.","Oral TNF-α inhibitor shows potential to disrupt current market; early-stage RA trials planned.","Data presented at 2023 Society of Toxicology Annual Meeting on March 20, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-008200","json":"https://secwatch.observer/filing/0001493152-23-008200.json","markdown":"https://secwatch.observer/filing/0001493152-23-008200.md","text":"https://secwatch.observer/filing/0001493152-23-008200.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1321834/000149315223008200/0001493152-23-008200-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1321834/000149315223008200/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T22:54:02.514213+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}